OREANDA-NEWS. Panda Capital Inc. (NEX:PDA.H) (the "Company") is pleased to announce that it has received conditional approval from the TSX Venture Exchange (the "TSXV") with respect to the proposed amalgamation (the "Transaction") between ABcann Medicinals Inc. ("ABcann"), the Company and a wholly-owned subsidiary of the Company formed for the purposes of completion of the amalgamation, which will result in the reverse takeover of the Company by ABcann and will constitute the Company’s Qualifying Transaction (as defined in the policies of the TSXV). A filing statement with respect to the Transaction is expected to be filed under the Company’s SEDAR profile at www.sedar.com on or about March 31, 2017. The Company and ABcann continue to work towards completion of the Transaction and closing is expected to occur on or about April 17, 2017.

Completion of the Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and if applicable pursuant to TSXV requirements, majority of the minority shareholder approval. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.